Claims for Patent: 9,981,018

Summary for Patent: 9,981,018

Title:	Compositions and methods for modulating toll-like receptor 2 activation
Abstract:	A method of promoting hair growth of a subject includes administering to follicle cells of the subject a therapeutically effective amount of a TLR2 agonist that promotes TLR2 activation and hair growth of the subject.
Inventor(s):	Byzova; Tatiana (Pepper Pike, OH)
Assignee:	The Cleveland Clinic Foundation (Cleveland, OH)
Application Number:	13/709,918
Patent Claims:	1. A method of promoting hair growth at a skin wound site of a mammalian subject, comprising: administering to the skin wound site of the mammalian subject a therapeutically effective amount of a TLR2 agonist that promotes TLR2 activation and hair growth of the mammalian subject, the TLR2 agonist comprising a carboxyethylpyrrole (CEP) adduct or pharmaceutically acceptable salts thereof. 2. The method of claim 1, wherein the therapeutically effective amount is the amount required to increase hair follicle density at the skin wound site of the subject. 3. The method of claim 1, the CEP adduct having the following formula: ##STR00003## wherein X is a peptide, polypeptide, small molecule, or polymer, and is bound to the amine of the CEP pyrrole or pharmaceutically acceptable salts thereof. 4. The method of claim 3, wherein X is selected from the group consisting of mouse serum albumin and human serum albumin. 5. A method of promoting hair growth at a skin wound site of a mammalian subject, comprising: administering to the skin wound site of the mammalian subject a therapeutically effective amount of a TLR2 agonist that promotes TLR2 activation and hair growth at the skin wound site of the mammalian subject, the TLR2 agonist comprising a carboxyethylpyrrole (CEP) adduct having the following formula: ##STR00004## wherein X is selected from the group consisting of a dipeptide, mouse serum albumin and human serum albumin, and is bound to the amine of the CEP pyrrole or pharmaceutically acceptable salts thereof. 6. The method of claim 5, wherein the therapeutically effective amount is the amount required to increase hair follicle density at the skin wound site of the subject. 7. A topical formulation for promoting hair growth at a skin wound site in a mammalian subject, the topical formulation comprising: a therapeutically effective amount of a carboxyethylpyrrole (CEP) adduct that promotes TLR2 activation and at least one carrier or pharmaceutically acceptable salts thereof, the topical formulation when administered to the skin wound site of the mammalian subject promoting hair growth at the skin wound site. 8. The topical formulation of claim 7, wherein the therapeutically effective amount is the amount required to increase hair follicle density at the skin wound site of the subject. 9. The topical formulation of claim 7, the CEP adduct having the following formula: ##STR00005## wherein X is a peptide, dipeptide, polypeptide, small molecule, or polymer, and is bound to the amine of the CEP pyrrole and or pharmaceutically acceptable salts thereof. 10. The topical formulation of claim 9, wherein X is selected from the group consisting of mouse serum albumin and human serum albumin. 11. A topical formulation for promoting hair growth at a skin wound site in a mammalian subject, the topical formulation comprising: a therapeutically effective amount of a carboxyethylpyrrole (CEP) adduct that promotes TLR2 activation and at least one carrier, the topical formulation when administered to the skin wound site of the subject promoting hair growth at the skin wound site, the CEP adduct having the following formula: ##STR00006## wherein X is selected from the group consisting of a dipeptide, mouse serum albumin and human serum albumin, and is bound to the amine of the CEP pyrrole or pharmaceutically acceptable salts thereof. 12. The topical formulation of claim 11, wherein the therapeutically effective amount is the amount required to increase hair follicle density at the skin wound site of the subject.

Details for Patent 9,981,018

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2030-06-08
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2030-06-08
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2030-06-08